Abstract: A questionable scientific approach to measuring at low concentrations and inappropriate censoring of results below certain cut-offs have resulted in the dichotomous classification of troponin assays based on their so-called analytical sensitivity. The definition of "high-sensitivity" cardiac troponin is flawed. Evidence suggests that its apparent diagnostic superiority may be explained by the censoring of data. In the evaluation of the detection and quantification capabilities of analytical methods we recommend alignment with International Union of Pure and Applied Chemistry (IUPAC) guidelines, including reporting of all results. This will allow the objective evaluation of the diagnostic performance of troponin assays and will render the current troponin assay classification and nomenclature obsolete.
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The redefinition of myocardial infarction (MI) in 2000 entrenched cardiac troponin as an important diagnostic criteria [1] . A paper in 2009 by Reichlin et al. [2] heralded the rise of the so-called "high-sensitivity cardiac troponin" (hs-cTn) assays. Manufacturers continuously introduced more analytically sensitive assays while a multitude of studies followed promoting the diagnostic performance of these assays. This culminated in a formal definition of the hs-cTn assays [3] . The release of hs-cTn assays into the USA by the FDA seems imminent.
hs-cTn assays are currently defined as follows: a CV of 10% or less at the 99th percentile of normal healthy individuals, and the ability to measure troponin at a concentration value above the limit of detection (LoD) for at least 50% (ideally >95%) of healthy individuals [3] . The perceived benefits of hs-cTn assays are many and varied. Examples are lowering the 99th percentile cutoff, improving diagnostic sensitivity, achieving accelerated diagnosis of myocardial infarction (MI), measuring troponin in healthy individuals, providing early and improved rule in and rule out of MI, providing reference intervals specific for sex [4] .
However, careful scrutiny exposes flaws -not only in the scientific basis underlying the definition of hs-cTnbut also in the application of basic laboratory science. A clear understanding of the scientific approach to measure close to zero is crucial to understand the issues at hand. A great deal of disagreement existed until Lloyd Currie's seminal paper on this topic in 1968. His approach was adopted by the International Union of Pure and Applied Chemistry (IUPAC) and the International Standards Organisation (ISO) and is the current norm [5] [6] [7] (Figure 1 ). It is based on hypothesis testing, where the limit of the blank (LoB) is used as the critical decision limit to decide whether a measurement (result) indicates detection, with a predefined certainty. On the other hand, the LoD is the lowest true concentration to provide a measurement signal that will be greater than the LoB with a defined probability. It refers to the capabilities of the measurement process and not to a decision limit to be used to categorize results as detected or not. In addition, IUPAC states categorically that all results, including those below the LoB, should be reported in conjunction with their respective uncertainties.
Censoring of results below the LoD as "unmeasurable" set in motion the drive towards developing hs-cTn assays. The reason why censoring occurs can be found in the Clinical and Laboratory Standards Institute guidelines on detection capability, which states -50 years postCurrie -that results below the LoD should be reported as "Non Detected" [8] . Not only is the act of censoring questionable, but also the use of LoD in deciding whether an analyte is detected or not [9] . Ironically using LoD as a censoring point leads to a 0.5 probability of false rejection (β error) and not 0.05 as set out in the original hypothesis. This practice has been described as being naïve and leading to an unnecessary loss of information [10] , and we have yet to see a compelling argument about its benefit.
The apparent improvement in risk stratification with "high-sensitivity assays" vs. "the contemporary assays" found in the literature can be partially or fully explained by the fact that a larger portion of the data of the "contemporary assays" is censored, thus unfairly disadvantaging the latter. This explains the difference in diagnostic performance between sensitive and less sensitive assays found by Reichlin et al. [2] as is clearly visible in their ROC curves.
The departure from the IUPAC defined scientific terms and principles has significant practical implications. Assays were classified into high-sensitivity and contemporary, based on their precision at low concentrations (between zero and the 99th percentile cutoff) -not according to analytical sensitivity (i.e. the slope of the dose-response curve). The assays with the better precision were erroneously assumed to be diagnostically more sensitive by having a lower 99th percentile cutoff. The distribution of cardiac troponin concentration is skewed to the right with the majority of healthy individuals having concentrations closer to zero. Thus, small variations in the LoD will result in a large variation in the amount of data censored and lost, disadvantaging contemporary versus high-sensitivity assays when comparing diagnostic performance. The LoD of assays has even been proposed as a decision point in rule-in/rule-out protocols, ignoring the fact that a hypothetically perfect assay will be worthless since all results will be above this limit.
Evidence showing weaknesses in the hs-cTn dogma is slowly albeit steadily appearing. It is possible to measure troponin in all samples and the smallest error in measurement occurs at zero [11] . Boeckel et al. [12] demonstrated that even an estimate of levels below the LoD leads to a superior prediction compared to a model with censored data. Parikh et al. [13] have shown that in communitybased cohorts, cardiac troponin T (cTnT) results between the LoB (limit of the blank) and the LoD (limit of detection) confer a worse prognosis than results below the LoB. This finding demonstrates that there is a continuum of risk associated with cTnT levels. Finally, we demonstrated that the perceived advantage in diagnostic performance is an artifact of censoring [14] .
In order to compare troponin assays and to get an objective picture of diagnostic performance, we recommend alignment with IUPAC and ISO principles. We advocate a fit-for-purpose approach, as elegantly explained by Thompson [10, 15] . In short, all results should be reported with their respective uncertainties. The dichotomous classification of assays should be eschewed and terms such as LoB and LoD reserved to describe the performance attributes of assays. The error in imprecision, in real terms, is the smallest at zero and increases linearly with an increase in concentration (Figure 1) . The notable increase in relative imprecision close to zero is explained by simple mathematics used in its calculation. With cardiac troponin testing it is more important to determine whether concentrations are increased than to distinguish low concentrations from zero, and even more importantly, whether the difference between serial results is significant. Delta values are proving to be crucial in the diagnosis of MI and uncertainty in measurement of an assay can be used to determine the size of the difference that can be deemed statistically significant [16] . In summary, the dichotomous classification of troponin assays and terms such as hs-cTn, should be discontinued and replaced by objective assay characteristics. All cTn results (even below the LoB) should be reported, which will require manufacturers to modify their methodology. The reporting of all results will eliminate the temptation to use performance characteristics of an assay as cutoff levels for clinical decisions. The industry and academic fraternity are heavily invested in troponin assays and these recommendations can be expected to be met with scepticism. However, they will create a sound scientific foundation on which to build, realise the full potential of troponin testing and result in a more efficient use of resources. In light of the issues exposed with troponin testing, we, the medical laboratory community should review and rectify our approach -in other words, align our guidelines with that of IUPAC and ISO -not only for troponin testing, but in general. This scientific approach will relegate the introduction of "hs-cTn" into the USA as the non-event it truly is.
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